Tracking Wegovy's impact on pregnant women and their babies
NCT ID NCT05872022
Summary
This study aims to understand the safety of the weight-loss medication Wegovy during pregnancy. Researchers will follow about 728 pregnant women—some taking Wegovy and some not—to compare health outcomes for both mothers and their babies. The study will track infants through their first year of life to look for any birth defects or developmental issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novo Nordisk Investigational Site
Princeton, New Jersey, 08540, United States
-
Novo Nordisk Investigational Site
Madrid, Spain
-
Novo Nordisk Investigational Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.